| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442562 | European Journal of Cancer | 2015 | 10 Pages |
Abstract
The significant OS benefit observed with the addition of nintedanib to docetaxel therapy was achieved with no detrimental effect on patient self-reported QoL.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Silvia Novello, Rolf Kaiser, Anders Mellemgaard, Jean-Yves Douillard, Sergey Orlov, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, José Barrueco, Birgit Gaschler-Markefski, Ingolf Griebsch, Michael Palmer,